Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 3/2006

01.09.2006 | Original Article

Clindamycin–paclitaxel pharmacokinetic interaction in ovarian cancer patients

verfasst von: Robert Fruscio, Andrea A. Lissoni, Roberta Frapolli, Silvia Corso, Costantino Mangioni, Maurizio D’Incalci, Massimo Zucchetti

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2006

Einloggen, um Zugang zu erhalten

Abstract

Introduction: Plasma protein binding is an important factor for many drugs that can influence the tissue distribution and pharmacokinetics. α1-acid glycoprotein (AGP) is an acute-phase protein that can increase in plasma of patients with several pathological conditions including cancer. Studies performed in cultured cells indicate that paclitaxel cytotoxicity is reduced by adding AGP and the sensitivity to paclitaxel is restored by displacing its binding to AGP with clindamycin, resulting in an increased paclitaxel cell uptake. The purpose of this study was to evaluate whether clindamycin modifies paclitaxel pharmacokinetics also in cancer patients. Patients and methods: Sixteen patients with advanced ovarian cancer, previously treated with surgery and chemotherapy were enrolled in this study. A pharmacokinetic study of paclitaxel was performed in the first three cycles of the consolidation therapy (paclitaxel and carboplatin) in each patient. In these cycles paclitaxel was administered alone and with two different doses (600 and 1,200 mg) of concurrent clindamycin. The sequence of the three treatments was randomly assigned in each patient in order to avoid the same order of treatments. Results: Paclitaxel pharmacokinetics were partly modified by the concurrent administration of clindamycin. C max and AUC0–last of paclitaxel were significantly higher when the drug was given alone than when it was coadministered with 1,200 mg clindamycin. Moreover, AGP concentrations seem to have a small but statistically significant influence on paclitaxel pharmacokinetic, since AUC0–last showed a positive significant correlation with AGP plasma concentration when paclitaxel was given alone. The linear relation was lost when paclitaxel was coadministered with 1,200 mg clindamycin. Toxicity was not influenced by the coadministration of clindamycin. Conclusion: The hypothesis that clindamycin could affect paclitaxel pharmacokinetics seems to be verified with this study. Nevertheless, changes induced by giving the combination of the two drugs are minimal and thus of questionable clinical relevance.
Literatur
1.
Zurück zum Zitat Chan S, Gerson B (1987) Free drug monitoring. Clin Lab Med 7:279–287PubMed Chan S, Gerson B (1987) Free drug monitoring. Clin Lab Med 7:279–287PubMed
2.
Zurück zum Zitat Barre J, Didey F, Delion F, Tillement JP (1988) Problems in therapeutic drug monitoring: free drug level monitoring. Ther Drug Monit 10:133–143PubMedCrossRef Barre J, Didey F, Delion F, Tillement JP (1988) Problems in therapeutic drug monitoring: free drug level monitoring. Ther Drug Monit 10:133–143PubMedCrossRef
3.
Zurück zum Zitat Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59:1454–1457PubMed Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59:1454–1457PubMed
4.
Zurück zum Zitat Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, van Zomeren DM, Verweij J, Sparreboom A (2002) Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol 20:574–581CrossRefPubMed Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, van Zomeren DM, Verweij J, Sparreboom A (2002) Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol 20:574–581CrossRefPubMed
5.
Zurück zum Zitat Kuvibidila S, Warrier RP, Yu L, Ode D, Mbele V (1994) Reference levels of acute phase reactant proteins in healthy Zairean women in the reproductive age group. J Trop Med Hyg 97:239–243PubMed Kuvibidila S, Warrier RP, Yu L, Ode D, Mbele V (1994) Reference levels of acute phase reactant proteins in healthy Zairean women in the reproductive age group. J Trop Med Hyg 97:239–243PubMed
6.
Zurück zum Zitat Piver MS, Moyer M, Diakun K, Lele SB, Chu TM (1988) Serum alpha 1-acid glycoprotein in epithelial ovarian cancer. Gynecol Oncol 29:305–308CrossRefPubMed Piver MS, Moyer M, Diakun K, Lele SB, Chu TM (1988) Serum alpha 1-acid glycoprotein in epithelial ovarian cancer. Gynecol Oncol 29:305–308CrossRefPubMed
7.
Zurück zum Zitat Elg SA, Mayer AR, Carson LF, Twiggs LB, Hill RB, Ramakrishnan S (1997) Alpha-1 acid glycoprotein is an immunosuppressive factor found in ascites from ovarian carcinoma. Cancer 80:1448–1456CrossRefPubMed Elg SA, Mayer AR, Carson LF, Twiggs LB, Hill RB, Ramakrishnan S (1997) Alpha-1 acid glycoprotein is an immunosuppressive factor found in ascites from ovarian carcinoma. Cancer 80:1448–1456CrossRefPubMed
8.
Zurück zum Zitat Harshman S, Reynolds VH, Neumaster T, Patikas T, Worrall T (1974) The prognostic significance of serial seromucoid analyses in patients with cancer. Cancer 34:291–299PubMedCrossRef Harshman S, Reynolds VH, Neumaster T, Patikas T, Worrall T (1974) The prognostic significance of serial seromucoid analyses in patients with cancer. Cancer 34:291–299PubMedCrossRef
9.
Zurück zum Zitat Fish RG, Yap AK, James K (1982) Changes in serum acute phase proteins in breast cancer patients receiving methotrexate infusion therapy. Clin Biochem 15:4–8CrossRefPubMed Fish RG, Yap AK, James K (1982) Changes in serum acute phase proteins in breast cancer patients receiving methotrexate infusion therapy. Clin Biochem 15:4–8CrossRefPubMed
10.
Zurück zum Zitat Fish RG, Gill TS, Adams M, Faqeera F, Kerby I (1984) Changes in serum acute phase proteins in ovarian cancer patients receiving cis-diamminedichloroplatinum (CDDP) infusion therapy. Clin Biochem 17:39–41CrossRefPubMed Fish RG, Gill TS, Adams M, Faqeera F, Kerby I (1984) Changes in serum acute phase proteins in ovarian cancer patients receiving cis-diamminedichloroplatinum (CDDP) infusion therapy. Clin Biochem 17:39–41CrossRefPubMed
11.
Zurück zum Zitat Ganz PA, Baras M, Ma PY, Elashoff RM (1984) Monitoring the therapy of lung cancer with alpha-1-acid glycoprotein. Cancer Res 44:5415–5421PubMed Ganz PA, Baras M, Ma PY, Elashoff RM (1984) Monitoring the therapy of lung cancer with alpha-1-acid glycoprotein. Cancer Res 44:5415–5421PubMed
12.
Zurück zum Zitat Kremer JM, Wilting J, Janssen LH (1988) Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 40:1–47PubMed Kremer JM, Wilting J, Janssen LH (1988) Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 40:1–47PubMed
13.
Zurück zum Zitat Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, Rossi F, Gianazza E, Brueggen J, Cozens R, Pioltelli P, Pogliani E, Corneo G, Formelli F, D’Incalci M (2000) Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 92:1641–1650CrossRefPubMed Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, Rossi F, Gianazza E, Brueggen J, Cozens R, Pioltelli P, Pogliani E, Corneo G, Formelli F, D’Incalci M (2000) Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 92:1641–1650CrossRefPubMed
14.
Zurück zum Zitat Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S, Tornaghi L, Rossi F, Pioltelli P, Pogliani E, Alberti D, Corneo G, D’Incalci M (2003) Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 9:625–632PubMed Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S, Tornaghi L, Rossi F, Pioltelli P, Pogliani E, Alberti D, Corneo G, D’Incalci M (2003) Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 9:625–632PubMed
15.
Zurück zum Zitat Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S (1998) Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res 58:3248–3253PubMed Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S (1998) Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res 58:3248–3253PubMed
16.
Zurück zum Zitat Bruno R, Vivler N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 24:153–172PubMedCrossRef Bruno R, Vivler N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 24:153–172PubMedCrossRef
17.
Zurück zum Zitat Plaisance KI, Drusano GL, Forrest A, Townsend RJ, Standiford HC (1989) Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother 33(5):618–620PubMed Plaisance KI, Drusano GL, Forrest A, Townsend RJ, Standiford HC (1989) Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother 33(5):618–620PubMed
Metadaten
Titel
Clindamycin–paclitaxel pharmacokinetic interaction in ovarian cancer patients
verfasst von
Robert Fruscio
Andrea A. Lissoni
Roberta Frapolli
Silvia Corso
Costantino Mangioni
Maurizio D’Incalci
Massimo Zucchetti
Publikationsdatum
01.09.2006
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 3/2006
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-005-0160-y

Weitere Artikel der Ausgabe 3/2006

Cancer Chemotherapy and Pharmacology 3/2006 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.